Nader Michael A MA

Show results for

Unknown (6)
Proteomics (2)
Transcriptomics (1)
Genomics (1)
Metabolomics (1)

Organisms

Homo sapiens (3)
Mus musculus (1)

Repository

pride (2)
biostudies-arrayexpress (1)
EGA (1)
MetaboLights (1)

Tissue

Brain (2)
Cell culture (1)

Disease

Alzheimer's disease (1)

Technology Type

Mass Spectrometry (2)
Shotgun proteomics (2)
Mass spectrometry (1)

Instrument Platform

Q Exactive (1)

Publication Date

2012 (1)
2024 (1)
2021 (1)
2020 (1)

CHEBI ID

CHEBI:111517 (1)
CHEBI:116314 (1)
CHEBI:11805 (1)
CHEBI:12937 (1)
CHEBI:12962 (1)
CHEBI:132477 (1)
CHEBI:132479 (1)
CHEBI:132948 (1)
CHEBI:132994 (1)
CHEBI:133005 (1)
CHEBI:133028 (1)
CHEBI:133032 (1)
CHEBI:133057 (1)
CHEBI:133066 (1)
CHEBI:133077 (1)
CHEBI:133092 (1)
CHEBI:133096 (1)
CHEBI:133115 (1)
CHEBI:133119 (1)
CHEBI:133139 (1)
CHEBI:133141 (1)
CHEBI:133144 (1)
CHEBI:133172 (1)
CHEBI:133176 (1)
CHEBI:133185 (1)
CHEBI:133186 (1)
CHEBI:133199 (1)
CHEBI:133435 (1)
CHEBI:133460 (1)
CHEBI:133469 (1)

Metabolite Name

(R)-3-hydroxybutyrylcarnitine (1)
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)* (1)
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4)* (1)
1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* (1)
1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2)* (1)
1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)* (1)
1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* (1)
1-(1-enyl-palmitoyl)-GPE (P-16:0)* (1)
1-(1-enyl-stearoyl)-GPE (P-18:0)* (1)
1-arachidonoyl-GPI (20:4)* (1)
1-lignoceroyl-GPC (24:0) (1)
1-linoleoyl-GPE (18:2)* (1)
1-linoleoyl-GPI (18:2)* (1)
1-methyl-4-imidazoleacetate (1)
1-methylguanidine (1)
1-methylhistidine (1)
1-methylnicotinamide (1)
1-myristoyl-2-palmitoyl-GPC (14:0/16:0) (1)
1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6)* (1)
1-oleoyl-2-linoleoyl-GPE (18:1/18:2)* (1)
1-oleoyl-GPI (18:1) (1)
1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4)* (1)
1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)* (1)
1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) (1)
1-palmitoyl-2-docosahexaenoyl-GPE (16:0/22:6)* (1)
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) (1)
1-palmitoyl-2-oleoyl-GPC (16:0/18:1) (1)
1-palmitoyl-2-oleoyl-GPI (16:0/18:1)* (1)
1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)* (1)
1-palmitoyl-2-stearoyl-GPC (16:0/18:0) (1)

Study type

Transcription profiling by array (1)

Release Date

2021 (3)
2012 (1)
2022 (1)
2016 (1)
2013 (1)

Lab affiliation

Department of Biological Engineering, Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA (1)
Department of Biological Engineering, Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA (lab head) (1)

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal-like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches can identify candidate genes whose inactivation contributes to ...

2024-04-02 | MTBLS9418 | MetaboLights

Automated, multiparametric monitoring of respiratory biomarkers and vital signs in clinical and home settings for COVID-19 patients.

Not available

S-EPMC8126790 | biostudies-literature

Phosphoproteomics identifies microglial Siglec-F inflammatory response during neurodegeneration

This study sought to explore phosphoproteome signaling dysregulation in different models of neurodegeneration. We collected phosphotyrosine, MAPK/CDK substrates, global phosphoproteome, and protein expression data from hippocampus and/or cortex tissue from each model. Tryptic peptides were multiplex...

ORGANISM(S): Mus musculus (Mouse)

2020-11-09 | PXD018757 | Pride

Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer’s disease

Alzheimer’s disease (AD) is a form of dementia characterized by amyloid-β plaques and Tau neurofibrillary tangles that progressively disrupt neural circuits in the brain. Using mass spectrometry, we performed a combined analysis of the tyrosine, serine, and threonine phosphoproteome, and proteome of...

ORGANISM(S): Homo sapiens (Human)

2021-05-25 | PXD020087 | Pride

Phosphoproteomics alzheimer's disease

The Genomic Analysis of Medulloblastoma

Medulloblastoma is a heterogenous disease made up of at least four distinct subtypes of disease which appear to exploit and disrupt naturally occurring developmental pathways of cellular growth and hindbrain development. To better understand the driver mutations of this disease, we performed whol...

phs000409.v1.p1 | EGA

Novel mutations target distinct subgroups of medulloblastoma.

Medulloblastoma is a malignant childhood brain tumour comprising four discrete subgroups. To identify mutations that drive medulloblastoma we sequenced the entire genomes of 37 tumours and matched normal blood. One hundred and thirty-six genes harbouring somatic mutations in this discovery set wer...

ORGANISM(S): Homo sapiens

2012-07-05 | E-GEOD-37418 | biostudies-arrayexpress

Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.

Not available

S-EPMC3934929 | biostudies-literature

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

Not available

S-EPMC4835977 | biostudies-literature

Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.

Not available

S-EPMC8206995 | biostudies-literature

SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.